CLINICAL EFFICACY OF ALBUMIN DIALYSIS THERAPY FOR PATIENTS WITH HEPATORENAL SYNDROME
https://doi.org/10.15825/1995-1191-2009-4-51-56
Abstract
34 patients (23 male, 11 female) in the age of 41–77 years (mean age 59,7 ± 4,2 years) with 2 type hepatorenal syndrome were included in the study. All patients were divided in 3 groups. The 1st group (n = 15) was treated by medical treatment, the 2nd group (n = 12) was treated by medical treatment and hemodiafiltration and the 3rd group (n = 7) – combined treatment with MARS therapy. Outcomes showed that combined therapy with addition of MARS provides positive results in treatment of the patients with 2 type hepatorenal syndrome.
About the Authors
D. E. Kutepov
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
I. N. Pasechnik
Federal State Institution «Training-scientific medical centre», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
N. P. Mironov
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
E. V. Tsygankov
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
A. V. Popov
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
O. K. Morochova
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
S. V. Stebletsov
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
E. Y. Kotselapova
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
M. G. Vershinina
Federal State Institution «Clinical hospital No 1», of Administrative department of President of RF, Moscow
Russian Federation
Russian Federation
References
1. Ивашкин В.Т. Болезни печени и желчевыводящих пу- тей: Руководство для врачей. 2-е изд. М.: М-Вести, 2005. 536 с.
2. Пасечник И.Н., Кутепов Д.Е. Печеночная недоста- точность: современные методы лечения. М.: МИА, 2009. 240 с.
3. Хазанов А.И., Плюскин С.В., Васильева А.П. и соавт. Различные формы большой печеночной недостаточ- ности: клинические особенности и исходы // Рос. журнал гастроэнтер., гепатол. и колопроктол. 2008. No 2. С. 18–27.
4. Шерлок Ш., Дули Дж. Заболевания печени и желч- ных путей. М.: ГЭОТАР-МЕД, 2002. 864 с.
5. Angeli P., Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis // J. Hepatol. 2008. Vol. 48. P. 93–103.
6. Arroyo V., Gines P., Gerbes A.L. et al. Definition and Diag- nostic Criteria of Refractory ascites and Hepatorenal Syn- drome in Cirrhosis // Hepatol. 1996. Vol. 23. P. 164–176.
7. Arroyo V., Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Ligt and shadows in an important clinical problem // J. Hepatol. 2000. Vol. 32 (Suppl. 1). P. 157–170.
8. Brensing K.A., Textor J., Perz J. et al. Long term outcome after Transjugular intrahepatic portosystemic shunt-shunt in nontransplant cirrhotics with hepatorenal syndrome a phase II study // Gut. 2000. Vol. 47. P. 288–295.
9. Christensen E. Prognostic models including Child-Pugh, MELD and Mayo risk scores-where are we where should we go? // J. Hepatol. 2004. Vol. 41. P. 344–350.
10. Dagher L., Moore K. The hepatorenal syndrome // Gut. 2001. Vol. 49. P. 729–737.
11. Davenport A. Гепаторенальный синдром // IV Меж- дународная конференция «Акт. аспекты экстракорп. очищения крови в интенсив. теp.». М., 2004. С. 5–13.
12. Dunn W., Jamil L.H., Brown L.S. et al. MELD accurately predicts mortality in patients with alcoholic hepatitis // Hepatology. 2005. Vol. 41. P. 353–358.
13. Eckardt K-U., Frei U. Reversibility of hepatorenal syndrome in an anuric patient with Child C cirrhosis requiring hemodialysis for 7 weeks. // Nephrol. Dial. Transplant. 2000. Vol. 15. P. 1063–1065.
14. Ginés P., Guevara M., Arroyo V. et al. Hepatorenal syndrome // Lancet. 2003. Vol. 362. P. 1819–1827.
15. Katoonizadeh A., Decaestecker J., Wilmer A. et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure // Liver Int. 2007. Vol. 27. P. 329–334.
16. Mitzner S.T., Stange J., Klammt S. et al. Improvent of Hepatorenal Syndrome With Extracorporeal Albumin Dialysis MARS: Result of a Prospective, Randomized, Controlled Clinical Trial. // Liver Traspl. 2000. Vol. 6. P. 277–286.
17. Mitzner S.T., Klammt S., Perzynski P. et al. Improvement of Multiple Organ Functions in Hepatorenal Syndrome During Albumin Dialysis with the Molecular Adsor- bent Recirculating System. // Ther. Apher. 2001. Vol. 5. P. 417–422.
18. Salerno F., Gerbes A., Ginès P. et al. Diagnosis, prevention, and treatment of hepatorenal syndrome in cirrhosis // Gut. 2007. Vol. 56. P. 1310–1318.
19. SortP.,NavasaM.,ArroyoV.etal.Effectofplasmavolume expansion on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis // N. Engl. J. Med. 1999. Vol. 341. P. 403–409.
20. Stange J., Hassanein T.I., Mehta R. et al. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical in- vestigation, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers // Artif. Or- gans. 2002. Vol. 26. P. 103–110.
Review
For citations:
Kutepov D.E., Pasechnik I.N., Mironov N.P., Tsygankov E.V., Popov A.V., Morochova O.K., Stebletsov S.V., Kotselapova E.Y., Vershinina M.G. CLINICAL EFFICACY OF ALBUMIN DIALYSIS THERAPY FOR PATIENTS WITH HEPATORENAL SYNDROME. Russian Journal of Transplantology and Artificial Organs. 2009;11(4):51-56. (In Russ.) https://doi.org/10.15825/1995-1191-2009-4-51-56
Views:
834
Email this article 